Loading…
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-105M | $-105M | $-88M | -22.5% | - | - |
| 2024 | - | - | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2024 | 2025 |
|---|---|---|
| Total Revenue | - | 0 |
| Operating Revenue | - | 0 |
| Operating Expense | - | 122.05 |
| Research And Development | - | 100.64 |
| Selling General And Administration | - | 21.41 |
| Total Expenses | - | 122.05 |
| Operating Income | - | -122.05 |
| Total Operating Income As Reported | - | -122.05 |
| EBITDA | - | -105.35 |
| Normalized EBITDA | - | -105.35 |
| EBIT | - | -105.43 |
| Interest Income | - | 16.63 |
| Interest Expense | - | 0 |
| Net Interest Income | - | 16.63 |
| Other Non Operating Income Expenses | - | -0.01 |
| Other Income Expense | - | -0.01 |
| Interest Income Non Operating | - | 16.63 |
| Interest Expense Non Operating | - | 0 |
| Net Non Operating Interest Income Expense | - | 16.63 |
| Pretax Income | - | -105.43 |
| Tax Rate For Calcs | - | 0 |
| Tax Effect Of Unusual Items | - | 0 |
| Net Income Continuous Operations | - | -105.43 |
| Net Income From Continuing And Discontinued Operation | - | -105.43 |
| Net Income From Continuing Operation Net Minority Interest | - | -105.43 |
| Net Income | - | -105.43 |
| Net Income Common Stockholders | - | -105.43 |
| Net Income Including Noncontrolling Interests | - | -105.43 |
| Normalized Income | - | -105.43 |
| Diluted NI Availto Com Stockholders | - | -105.43 |
| Basic Average Shares | - | 45.61 |
| Diluted Average Shares | - | 45.61 |
| Reconciled Depreciation | - | 0.08 |
| General And Administrative Expense | - | 21.41 |
| Other Gand A | - | 6.38 |
| Salaries And Wages | - | 15.03 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Oruka Therapeutics, Inc.this co. | ORKA | $3.8B | - | 9.90 | -22.5% | - |
| Travere Therapeutics, Inc. | TVTX | $4.3B | -168.11 | 37.40 | -22.2% | 203.89 |
| 10x Genomics, Inc. | TXG | $4.3B | -97.67 | 5.34 | -5.5% | 988.34 |
| Erasca, Inc. | ERAS | $4.1B | -33.13 | 12.69 | -38.3% | -31.96 |
| LivaNova PLC | LIVN | $4.0B | -16.70 |
| 3.37 |
| -20.2% |
| -34.40 |
| Edgewise Therapeutics, Inc. | EWTX | $4.0B | -23.87 | 7.67 | -32.1% | -20.88 |
| Crinetics Pharmaceuticals, Inc. | CRNX | $3.7B | -7.85 | 3.68 | -46.9% | -7.02 |
| iRhythm Holdings, Inc. | IRTC | $3.5B | -79.19 | 23.10 | -29.2% | -1014.62 |
| Beam Therapeutics Inc. | BEAM | $3.4B | -42.24 | 2.73 | -6.5% | -8.96 |
| Peer Median | - | -37.69 | 6.51 | -25.7% | -14.92 | |